FibroGen Financial Statements
FibroGen Financial Overview
FibroGen's market cap is currently ―. The company's EPS TTM is $-3.04; its P/E ratio is -3.75; FibroGen is scheduled to report earnings on August 8, 2022, and the estimated EPS forecast is $-0.92. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 60.83M | $ 16.54M | $ 155.97M | $ 24.36M | $ 38.43M |
| Gross Profit | $ 56.59M | $ 13.42M | $ 152.71M | $ 21.29M | $ 35.03M |
| EBIT | $ -62.99M | $ -135.24M | $ 50.97M | $ -133.84M | $ -70.43M |
| EBITDA | $ -60.41M | $ -132.66M | $ 53.56M | $ -129.54M | $ -65.09M |
| Net Income Common Stockholders | $ -63.20M | $ -134.08M | $ 49.80M | $ -133.99M | $ -71.75M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 405.19M | $ 428.07M | $ 486.40M | $ 507.21M | $ 544.23M |
| Total Assets | $ 745.93M | $ 773.82M | $ 850.51M | $ 808.62M | $ 787.30M |
| Total Debt | $ 36.29M | $ 37.09M | $ 40.78M | $ 96.93M | $ 101.09M |
| Net Debt | $ -368.90M | $ -390.99M | $ -445.62M | $ -410.29M | $ -443.14M |
| Total Liabilities | $ 567.92M | $ 544.71M | $ 505.45M | $ 528.77M | $ 397.03M |
| Stockholders Equity | $ 158.05M | $ 209.15M | $ 260.58M | $ 325.79M | $ 371.00M |
| Cash Flow | |||||
| Free Cash Flow | $ -45.11M | $ -56.36M | $ 17.68M | $ -28.24M | $ -45.50M |
| Operating Cash Flow | $ -8.48M | $ -54.96M | $ 44.26M | $ -26.54M | $ -44.98M |
| Investing Cash Flow | $ 25.93M | $ -50.57M | $ -122.15M | $ -57.53M | $ -196.72M |
| Financing Cash Flow | $ -2.89M | $ -31.00K | $ -833.00K | $ 2.38M | $ -2.08M |